VistaGen Therapeutics to Present at Two Investor Conferences in June
20 mai 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to...
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer
04 mai 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
27 avr. 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
22 mars 2021 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
16 mars 2021 07h46 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of...
VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
11 mars 2021 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation...
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
11 févr. 2021 16h30 HE
|
VistaGen Therapeutics, Inc.
Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder...
VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
06 janv. 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders
30 déc. 2020 09h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
22 déc. 2020 16h01 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of...